Primary aldosteronism during long-term ulcerative colitis: a diagnostic challenge

John K. Triantafillidis, George Malgarinos, Achilleas Rentis, Konstantinos Vagianos
Iaso General Hospital, Athens, Greece

Primary aldosteronism (PA) represents an important cause of secondary hypertension. This situation is currently increasingly being diagnosed accounting for more than 10% of patients with secondary hypertension [1]. It is characterized by a variety of clinical features including cardiovascular, renal, and metabolic consequences, especially hypokalemia [2].

Ulcerative colitis (UC) often requires large doses of corticosteroids in order for the flare-ups to be settled. Hypertension or aggravation of already existing hypertension represents a well-known side effect related to the administration of corticosteroids. Significant losses of potassium could also appear during prolonged administration of corticosteroids for UC [3]. Thus, UC and PA may have overlapping manifestations.

So far, there is only one report referring to two cases of PA appearing during the course of Crohn’s disease [4]. A coexistence of PA with UC has not yet been described.

The case described herein refers to a male patient, aged 49, who suffered from UC since the age of 33. The left-sided UC ran with remissions and exacerbations of mild to moderate severity once every 2 or 3 years. During the flare-ups he received short (4 to 8 weeks) courses of prednisone (30 mg/d orally in reduced doses) plus mesalamine (3.2 g/d orally; and 4 g/d in the form of enemas). Current maintenance treatment consisted of oral mesalamine 1.6 g/d and azathioprine 2 mg/kg/d.

During the last two years, he noticed a mild elevation in blood pressure, managed with oral diuretics and β-blockers (combination of atenolol and chlortalidone 50 and 12.5 mg, respectively). In September 2011, he complained of fatigue, myalgias, and mild epigastric pain. Hypokalemia was noticed, erroneously attributed to the use of diuretics. Despite the oral administration of potassium, hypokalemia persisted.

On admission, physical examination revealed hypertension (180/100 mmHg) and arrhythmia. Routine blood tests, including complete blood count, C-reactive protein, and liver and renal function tests, were normal. Erythrocyte sedimentation rate was 45 mm/1st h. Abdominal computed tomography, celiac and renal artery angiography, and cardiac Doppler ultrasound, revealed no significant findings. However, hormonal evaluation confirmed the diagnosis of PA due to adrenal hyperplasia. The values of aldosterone in both decubitus and upright position were significantly increased. Serum renin level and renin activity were abnormal (Table 1). Underlying bowel disease was quiescent.
Table 1 Results of serum hormonal and urine (24 h) estimation

| Parameter                        | Result | Normal values                          |
|----------------------------------|--------|----------------------------------------|
| Cortisol (μg/dL)                 | 16.4   | 7.0-25.0 (morning)                     |
|                                  | 5.6    | 2.0-9.0 (evening)                      |
| ACTH (pg/mL)                     | 33.7   | 7.0-64.0 (morning)                     |
|                                  | 18.2   | 5.0-30.0 (evening)                     |
| Renin (pg/mL)                    |        |                                        |
| (decubitus position)             | 0.20   | 1.10-20.20                             |
| (upright position)               | 0.20   | 1.80-39.40                             |
| Renin activity (ng/mL/h)         |        |                                        |
| (decubitus position)             | 0.01   | 0.20-1.40                              |
| (upright position)               | 0.01   | 0.50-4.70                              |
| Aldosterone (ng/dL)              |        |                                        |
| (decubitus position)             | 45.3   | 1.0-16.0                               |
| (upright position)               | 66.3   | 4.0-31.0                               |
| Urine vanillylmandelic acid (mg/24h) | 3.7  | 1.8-6.7                               |
| Urine metanephrines (μg/24h)     | 460.0  | 100.0-800.0                            |
| Urine free cortisol (μg/24h)     | 75.2   | 20.0-90.0                              |
| Urine aldosterone (μg/24h)       | 23.9   | 2.8-30.0                               |
| Urine hydroxyproline (mg/24h/m²) | 13.8  | 6.0-22.0                               |
| Urine creatinine (mg/dL)         | 306.0  | 30-125                                 |
| Urine Na⁺ (mg/dL)                | 42.0   | 20-110                                 |
| Urine K⁺ (mg/dL)                 | 76.8   | 12-62                                  |

ACTH, adrenocorticotropic hormone

In our case, the appearance of PA during the course of UC is probably coincidental. However, we suggest that clinicians should bear in mind the possibility of the concurrent existence of the two situations when managing a patient with UC and hypertension, especially if hypokalemia is present.

References

1. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. *Lancet* 2008;371:1921–1926.
2. Sukor N. Primary aldosteronism: from bench to bedside. *Endocrine* 2012;41:31-39.
3. Triantafillidis JK, Georgopoulos F, Merikas E. Current and emerging drugs for the treatment of inflammatory bowel disease. *Drug Des Devel Ther* 2011;5:185-210.
4. Astegiano M, Bresso F, Demarchi B, et al. Association between Crohn’s disease and Conn’s syndrome. A report of two cases. *Paminnerva Med* 2005;47:61-64.
5. Ye F, Tang ZY, Wu JC, et al. Hormones other than aldosterone may contribute to hypertension in 3 different subtypes of primary aldosteronism. *J Clin Hypertens (Greenwich)* 2013;15:264-269.
6. Samavat S, Ahmadpoor P, Samadian F. Aldosterone, hypertension, and beyond. *Iran J Kidney Dis* 2011;5:71-76.

IBD Unit, IASO General Hospital, Athens, Greece

Conflict of Interest: None

Correspondence to: Prof. John K. Triantafillidis, Iera Odos 354, Haidari, 12461, Athens, Greece, Tel.: 6944432917, e-mail: jktrian@gmail.com

Received 3 May 2014; accepted 15 May 2014